metastatic, non-squamous NSCLC, without EGFR mutation
Paclitaxel + Carboplatin + Bevacizumab (ECOG 4599) x 6
Maintenance Bevacizumab, until disease progression
Progression
Pemetrexed
Progression 2
Erlotinib
metastatic, non-squamous NSCLC, without EGFR mutation
Paclitaxel + Carboplatin + Bevacizumab (ECOG 4599) x 6
Maintenance Bevacizumab, until disease progression
Progression
Pemetrexed
Progression 2
Erlotinib